Oral TYK2 Inhibition in Atopic Dermatitis - Quiz - MDSpire

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.

  • By

  • Kathryn Wighton

  • February 5, 2026

  • 4 min

Share

Original Source(s)

Oral TYK2 Inhibition in Atopic Dermatitis

  • by Kathryn Wighton

  • February 5, 2026

Related Content

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

Studies on allergic diseases and B cells in the past 20 years: a bibliometric analysis via CiteSpace and VOSviewer

Editorial: Exploring Cutaneous Drug-Related and Drug-Associated Adverse events: from Clinical Insights to Therapeutic Management